Part of the book: Studies in Population Genetics
Part of the book: Methylation
Liquid biopsies contain numerous proteins coming from extracellular vesicles (EVs), be it microvesicles or exosomes, released by both normal and tumour cells, as well as the presence of any circulating tumour cells (CTCs). Such proteins can be used as biomarkers for early diagnosis, prognostic assessment, disease progression monitoring, therapy selection and treatment response, particularly in oncology. EVs have been identified as mediators of cell-to-cell communication in both normal and pathological conditions and suggested to play a role in promoting and maintaining cancer dissemination and progression by altering the tumour microenvironment through immune suppression, angiogenesis and metastasis. One class of proteins garnering particular interest are extracellular heat shock proteins (HSPs) (secreted despite no consensus secretory sequence), and their post-translational modifications (PTMs), which are thought to act as key players in intercellular crosstalk and activation of signalling pathways during stress conditions. This review will focus on how characterising and quantifying these proteins can indicate the condition of the physiological system in a variety of pathological contexts.
Part of the book: Liquid Biopsy
Emerging evidence indicates that among the various pregnancy complications, pre-eclampsia and gestational diabetes mellitus (GDM) seem to have, at least in part, shared underlying ethiologies. Apart from sharing numerous risk factors, it has been shown that the rate of pre-eclampsia is influenced by the presence and severity of GDM, with hyperglycemia due to insulin resistance and the biochemical changes this brings about (angiogenic imbalance, oxidative stress and inflammation), playing some role in the pathogenesis of endothelial dysfunction leading to the development of pre-eclampsia. However, so far the biochemical mechanisms underlying and linking these two conditions is still not properly understood. The altered physiological parameters, dysregulation of potential protein biomarkers and DNA-related changes (mutations, methylations, miRNAs) will be combined in this review to explore possible underlying mechanisms.
Part of the book: Prediction of Maternal and Fetal Syndrome of Preeclampsia
Colorectal cancer (CRC) remains one of the most frequently diagnosed tumours worldwide. Despite advances in surgical intervention and therapeutics, development of chemoresistance remains a challenge to treating CRC. Predicting treatment response in CRC has strongly relied on genomics, transcriptomics and epigenomics, combined with different cancer staging and classification systems. Despite being beneficial, these omics technologies fail to provide any assessment at a protein level. Thus, having high-throughput tools that assess tumour response to therapy at a protein level will definitely complement the current approaches. In this regard, the field of proteomics holds promise to understand treatment response in tumours. Additionally, patient-derived tumour organoids are replacing the traditional cell lines and xenograft models as the preferred in vitro models for predicting clinical response due to being a better representative model of typical tumour characteristics in vivo. Combining proteomics and tumour organoids can provide more personalised and optimal treatments for CRC in the coming years. This chapter aims to provide an overview of the progress made in proteomic research and use of organoids for understanding CRC treatment response, together with discussing the strengths and limitations of these two approaches when linked together. This overview will then be used to propose future perspectives.
Part of the book: Recent Understanding of Colorectal Cancer Treatment